Floatz logo

Pasireotide

Pancreatic Fistula

Helsinki University Central Hospitalprotein_peptidePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pancreatic Fistula cohort.

Asset / SponsorPhaseRating
Solu-Cortef
Helsinki University Central Hospital
Phase 4B
Glubran 2
Minia University
Phase 2CCC
NORMAL HUMAN SERUM ALBUMIN
Universiti Kebangsaan Malaysia Medical Centre
Phase 2CCC

Same molecule, other indications

Pasireotide is also rated in:

prostate cancerDormant
BB
Indicative ·
69 / 100
View asset →
neuroendocrine neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
dumping syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →